See what’s in our product pipeline

We're investing in research and development to offer more solutions to challenges in transplant. Get to know our product pipeline and see our investment in the future.

product pipeline

Our future (in development)

We’re living up to our commitment to transform transplant medicine by leveraging our research and development capabilities to discover new therapies.

Veloxis Corporate PipelineVeloxis Corporate Product Pipeline
Click to expand image description

Veloxis Pipeline & Investments:


  • Therapeutic Area: Transplantation (Immunology)
  • Name: VEL101
  • Indication: SOT
  • Type/Region: License/Global
  • Phase: Phase 1

Asahi Kasei Pipeline:

ART-123 – CIPN

  • Therapeutic Area: Critical Care
  • Name: ART-123
  • Indication: CIPN
  • Type/Region: In-house/Global
  • Phase: Phase 1

AK1820 (isavuconazole)

  • Therapeutic Area: Critical Care
  • Name: AK1820 (isavuconazole)
  • Indication: anti-fungal
  • Type/Region: License/Japan
  • Phase: Filed/Market


  • Therapeutic Area: Musculoskeletal
  • Name: AK1830
  • Indication: OA pain
  • Type/Region: License/Japan
  • Phase: Phase 2

HE-69 (mizoribine)

  • Therapeutic Area: Nephrology
  • Name: HE-69 (mizoribine)
  • Indication: lupus nephritis
  • Type/Region: In-house/China
  • Phase: Filed/Market
Joint development program for ART-123 in US and Japan.

SOT=solid organ transplant; CIPN=chemotherapy-induced peripheral neuropathy; OA=osteoarthritis
SOT=solid organ transplant; CIPN=chemotherapy-induced peripheral neuropathy; OA=osteoarthritis.

VEL-101 Clinical Program

VEL-101, a novel investigational immunosuppressant formerly known as FR104, is a monoclonal antibody fragment that inhibits costimulation via direct CD28 blockade.1 VEL-101 will be developed as a subcutaneous, at-home self-administration medication that may eliminate many of the toxicities seen with current standard of care immunosuppression.2

CD28 plays an essential role in T-cell activation, while CTLA-4 plays a key role in preventing or regulating T-cell activation.1,3,4 As a direct blocker of CD28 on the T cell, VEL-101 has a unique mechanism of action. Direct blockade of CD28 on the T cell with VEL-101 preserves vital CTLA-4 inhibitory functions.1,3,4 As a result of VEL-101's unique mechanism of action, it will be studied for prevention of acute rejection, preservation of regulatory T-cell function, and inhibition of donor-specific antibody production.3,4

Animal and initial human studies have been completed with VEL-101, and based on the results, the development program is continuing.1,3

See study publication
1. Poirier N, Blancho G, Hiance M, et al. First-in-human study in healthy subjects with FR104, a pegylated monoclonal antibody fragment antagonist of CD28. J Immunol. 2016;197(12):4593-4602. 2. US National Institutes of Health, National Library of Medicine. A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101 [NCT05238493]. 3. Poirier N, Mary C, Dilek N, et al. Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab' antibody. Am J Transplant. 2012;12(10):2630-2640. 4. Poirier N, Dilek N, Mary C, et al. FR104, an antagonist anti-CD28 monovalent fab' antibody, prevents alloimmunization and allows calcineurin inhibitor minimization in nonhuman primate renal allograft. Am J Transplant. 2015;15(1):88-100.

Let’s bring research to reality

Learn more about opportunities to partner with Veloxis.

Partner with us

Keep up-to-date on product pipeline and future R&D plans

Sign up for product updates and more news from Veloxis Pharmaceuticals. Your contact information will be used only for communications from Veloxis. Please review our Privacy Policy to learn more about how we use your information.

*Required fields.